Fintepla's weight-based list price near $96,000/year runs roughly 3x Epidiolex, and that gap, against a small, severe paediatric population, is the pressure point payers work through step-edits and rebate negotiation.
In the US, Dravet-specific therapy sits on the Part D pharmacy benefit layered over a generic valproate/clobazam backbone. Payer scrutiny is driven less by any single HTA verdict than by high list prices against a very small, severe paediatric population and by reliance on indirect, cross-trial comparison between agents never studied head-to-head. Fenfluramine (Fintepla, UCB) and cannabidiol (Epidiolex, Jazz) are the two branded Dravet-specific options; stiripentol (Diacomit, Biocodex) is adjunct-only. Neither Epidiolex nor Fintepla is a controlled substance (Epidiolex was descheduled in 2020 and fenfluramine in 2022), so both route through the standard Part D pharmacy benefit.
Price separates the class. Fenfluramine (Fintepla) carries a weight-based list price averaging near $96,000/year; cannabidiol (Epidiolex) lists near $32,000/year — roughly a 3x differential within the same Dravet-specific class, with no generic cannabidiol yet on the US market (ANDA litigation settled to launch dates in the late 2030s). Fintepla's REMS cardiac-monitoring requirement adds echocardiography cost that payers treat as prior-authorisation documentation. The combination drives step-edit pressure to trial lower-cost cannabidiol before fenfluramine, despite fenfluramine's stronger efficacy in its pivotal trial.
US Dravet-specific agent payer & HTA summary — 2026
| Drug (Brand / INN) | Benefit Routing | Annual WAC | Value / Access Note | PA Criteria (Commercial) | Key Payer Risk |
|---|---|---|---|---|---|
| Epidiolex (cannabidiol) | Part D (pharmacy benefit) | ~$32K/yr | Lower-cost branded option; no US generic yet (settled to late 2030s) | Confirmed Dravet (SCN1A or clinical); age-specific thresholds | State Medicaid formulary limits; step-edit gate role |
| Fintepla (fenfluramine) | Part D; REMS | ~$96K/yr (weight-based) | ~3x Epidiolex list price; stronger pivotal efficacy | Confirmed Dravet; REMS enrolment; step-edit after cannabidiol at some plans | ~3x cost premium; REMS echo-monitoring cost |
| Diacomit (stiripentol) | Part D; adjunct only | ~$10K–$15K | Adjunct-only positioning on valproate/clobazam | Adjunct to valproate + clobazam documented; standalone use denied | Adjunct-only coverage; narrow eligible population |
Sources: UCB/Zogenix Fintepla pricing disclosures (2020 launch); Jazz Pharmaceuticals Epidiolex pricing and 10-K disclosures; Fintepla FDA label and REMS; DEA descheduling notices (Epidiolex 2020, fenfluramine 2022).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The high WAC against a small, severe paediatric population
- the reliance on indirect cross-trial comparison
- how list price and rebate negotiation anchor commercial access for cannabidiol and fenfluramine
Delivers
- The ~3x cost differential
- lower-cost cannabidiol as a first-line step-edit gate
- the efficacy-versus-cost trade-off payers must resolve
- REMS monitoring cost as a PA factor
Delivers
- Routing to the Part D pharmacy benefit (neither agent is a controlled substance)
- state Medicaid formulary variation
- PA documentation requirements including SCN1A/clinical confirmation and Fintepla REMS enrolment
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why Dravet therapy routes through Part D pharmacy benefit atop a generic valproate-clobazam backbone, not a specialty medical benefit.
- How scrutiny stems from high list prices against a small paediatric population and cross-trial comparisons, not a single HTA verdict.
- Why the ~3x list-price gap between Fintepla ($96K) and Epidiolex ($32K) anchors indirect cross-trial value comparisons.
- How ANDA litigation settlements delaying generic cannabidiol until the late 2030s sustain Epidiolex's branded pricing power.
- How Fintepla's REMS cardiac-monitoring requirement adds echocardiography costs that payers fold into rebate negotiations.
- Why Diacomit's ~$10K-$15K adjunct-only pricing sits far below both Fintepla and Epidiolex in rebate leverage.
- Why Epidiolex's 2020 and fenfluramine's 2022 DEA descheduling let both drugs route through standard Part D benefit design.
- How non-controlled-substance status removes DEA scheduling barriers that would otherwise complicate Part D formulary placement.
- Why commercial plans step-edit patients through lower-cost Epidiolex before allowing Fintepla despite its stronger pivotal efficacy.
- How PA criteria require confirmed Dravet diagnosis (SCN1A or clinical) plus REMS enrolment for Fintepla approval.
- How state Medicaid formularies vary in step-edit gate placement between cannabidiol and fenfluramine across programs.
- Why Diacomit's adjunct-only positioning on valproate plus clobazam narrows its eligible Medicaid population versus the other two agents.
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Every AXLRx assessment is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer and HTA documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US Dravet Syndrome Payer & HTA sources: UCB/Zogenix and Jazz Pharmaceuticals list-price disclosures; the Fintepla FDA label and REMS requirement; and DEA descheduling notices (Epidiolex 2020, fenfluramine 2022). Underlying clinical-efficacy claims are drawn from the pivotal trials verified in the AXLRx Dravet competitive-intelligence brief (GWPCARE1, NEJM 2017, PMID 28538134; fenfluramine Study 1, Lancet 2019, PMID 31862249).
- Fintepla and Epidiolex list pricing verified against UCB/Zogenix and Jazz Pharmaceuticals disclosures
- Controlled-substance status verified against DEA notices — Epidiolex descheduled 2020, fenfluramine descheduled 2022 (neither is scheduled)
- Fintepla REMS cardiac-monitoring requirement verified against the FDA label
Frequently asked questions
Commission this assessment
AXLRx US Dravet Syndrome Payer & HTA is built for market access, HEOR, and pricing teams navigating the Fintepla-Epidiolex list-price gap, REMS monitoring cost, and Part D access in the US Dravet market. Custom assessment in 72 hours.
Specify indication, payer focus (pricing, PA criteria, step-edit design), and commercial question.
AXLRx analyst confirms payer scope, HTA framing, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.